The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1275 articles
A shocking University of Pennsylvania study links popular GLP-1 weight loss drugs to a 30% higher risk of osteoporosis and dramatic rises in other bone-weakening conditions. Hollywood stars chasing rapid fat loss may face painful complications like fractures and tendon ruptures. Experts warn that even small risk increases can be devastating for individuals.
The viral term 'Ozempic penis' suggests semaglutide increases size, but urologists clarify it's a visual illusion from fat loss. We explore the real, complex effects of GLP-1 medications on sexual health, from potential erection improvements to libido changes.
A groundbreaking study reveals that Ozempic and other GLP-1 medications like semaglutide significantly lower risks of depression, anxiety, addiction, and even suicidal behavior. Analyzing nearly 100,000 people, researchers found up to 47% reductions in related hospital visits and work absences. This could transform treatment for those with overlapping metabolic and mental health issues.
Indian pharma leaders Sun Pharma, Dr Reddy's, and Glenmark have launched generic semaglutide injections in India, slashing costs compared to Ozempic and Wegovy after patent expiry. With weekly prices starting at Rs 325, these options make GLP-1 therapy accessible for type 2 diabetes and weight management. Zydus joins with more affordable brands, transforming treatment affordability.
Ozempic and other GLP-1 medications promise weight loss and health gains, but they're fueling toxic body image problems in the gay community. Queer celebs like Margaret Cho and Boy George are praising the drugs, yet experts highlight risks to body confidence and even the ability to bottom. No studies yet focus on LGBTQ+ users, but the impacts are real.
Single mum Rebecca Tidy transformed her life by losing six stone on Mounjaro, but the real game-changer was the confidence boost that doubled her income. After ditching Saxenda due to side effects, Mounjaro helped her reclaim control. Here's her inspiring journey from exhaustion to empowerment.
The latest Morning Squawk highlights the Dow's ongoing losing streak, climbing fertilizer prices, and Novo Nordisk's new Wegovy shot amid market volatility. President Trump ramps up criticism of Fed Chair Jerome Powell, urging continued investigation into the 'incompetent' leader. A judge's subpoena block adds tension to Trump's Fed nominee confirmation.
Jefferies has reiterated its Buy rating on Eli Lilly stock with a $1,300 price target, citing encouraging GLP-1 prescription data for the week ending March 13. Oral Wegovy showed strong performance in its 10th launch week, outpacing comparable injectables like Zepbound and Wegovy. Meanwhile, other GLP-1s saw slight declines amid Lilly's promising pipeline.
More than 10% of U.S. adults use GLP-1 drugs like Ozempic and Wegovy, but one in seven microdose for longevity without major weight loss or side effects, per Evidation survey. Biohackers and clinics like AgelessRx promote it for reducing inflammation and chronic disease risks. Yet experts caution on unproven claims and sourcing risks.
